Evaluation of Serum Ferritin, Creatinine, and Liver Enzymes in Patients with Beta-Thalassemia After Administration of Deferasirox

    April 2023 in “ Tikrit Journal of Pharmaceutical Sciences ”
    Mohammed Adress Younis
    Studysummary In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tjphs.tu.edu.iq →
    Discuss this study in the Community →